Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms.

Schneider KL, Kunst M, Leuchs AK, Böhme M, Weckbecker K, Kastenmüller K, Bleckwenn M, Holdenrieder S, Coch C, Hartmann G, Stingl JC.

Front Pharmacol. 2020 Jan 28;10:1620. doi: 10.3389/fphar.2019.01620. eCollection 2019.

2.

Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study.

Gliem M, Birtel J, Herrmann P, Fimmers R, Berger M, Coch C, Wingen A, Holz FG, Charbel Issa P.

Graefes Arch Clin Exp Ophthalmol. 2020 Feb;258(2):311-318. doi: 10.1007/s00417-019-04551-4. Epub 2019 Dec 20.

PMID:
31863395
3.

Interferon-beta-induced changes in neuroimaging phenotypes of appetitive motivation and reactivity to emotional salience.

Coch C, Viviani R, Breitfeld J, Münzer K, Dassler-Plencker J, Holdenrieder S, Coenen M, Steffens M, Müller M, Hartmann G, Stingl J.

Neuroimage Clin. 2019;24:102020. doi: 10.1016/j.nicl.2019.102020. Epub 2019 Nov 14.

4.

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.

Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N.

Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.

PMID:
31488360
5.

Human TLR8 Senses RNA From Plasmodium falciparum-Infected Red Blood Cells Which Is Uniquely Required for the IFN-γ Response in NK Cells.

Coch C, Hommertgen B, Zillinger T, Daßler-Plenker J, Putschli B, Nastaly M, Kümmerer BM, Scheunemann JF, Schumak B, Specht S, Schlee M, Barchet W, Hoerauf A, Bartok E, Hartmann G.

Front Immunol. 2019 Mar 27;10:371. doi: 10.3389/fimmu.2019.00371. eCollection 2019.

6.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
7.

Effect of transcutaneous vagus nerve stimulation on muscle activity in the gastrointestinal tract (transVaGa): a prospective clinical trial.

Hong GS, Pintea B, Lingohr P, Coch C, Randau T, Schaefer N, Wehner S, Kalff JC, Pantelis D.

Int J Colorectal Dis. 2019 Mar;34(3):417-422. doi: 10.1007/s00384-018-3204-6. Epub 2018 Dec 5.

PMID:
30519842
8.

Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.

Daßler-Plenker J, Paschen A, Putschli B, Rattay S, Schmitz S, Goldeck M, Bartok E, Hartmann G, Coch C.

Int J Cancer. 2019 Apr 1;144(7):1645-1656. doi: 10.1002/ijc.31874. Epub 2019 Jan 9.

9.

Influence of Chitosan Treatment on Surrogate Serum Markers of Cholesterol Metabolism in Obese Subjects.

Lütjohann D, Marinova M, Wolter K, Willinek W, Bitterlich N, Coenen M, Coch C, Stellaard F.

Nutrients. 2018 Jan 11;10(1). pii: E72. doi: 10.3390/nu10010072.

10.

RIG-I Activation Protects and Rescues from Lethal Influenza Virus Infection and Bacterial Superinfection.

Coch C, Stümpel JP, Lilien-Waldau V, Wohlleber D, Kümmerer BM, Bekeredjian-Ding I, Kochs G, Garbi N, Herberhold S, Schuberth-Wagner C, Ludwig J, Barchet W, Schlee M, Hoerauf A, Bootz F, Staeheli P, Hartmann G, Hartmann E.

Mol Ther. 2017 Sep 6;25(9):2093-2103. doi: 10.1016/j.ymthe.2017.07.003. Epub 2017 Jul 8.

11.

RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.

Engel C, Brügmann G, Lambing S, Mühlenbeck LH, Marx S, Hagen C, Horváth D, Goldeck M, Ludwig J, Herzner AM, Drijfhout JW, Wenzel D, Coch C, Tüting T, Schlee M, Hornung V, Hartmann G, Van den Boorn JG.

Cancer Immunol Res. 2017 Jun;5(6):455-467. doi: 10.1158/2326-6066.CIR-16-0129-T. Epub 2017 May 3.

12.

Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.

Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K, Goehler K, Iovino M, Kammerer KP, Mikus G, Rengelshausen J, Sourgens H, Schinzel R, Sudhop T, Wensing G.

Eur J Clin Pharmacol. 2017 Apr;73(4):409-416. doi: 10.1007/s00228-016-2189-8. Epub 2017 Jan 7. Review.

13.

RIG-I activation induces the release of extracellular vesicles with antitumor activity.

Daßler-Plenker J, Reiners KS, van den Boorn JG, Hansen HP, Putschli B, Barnert S, Schuberth-Wagner C, Schubert R, Tüting T, Hallek M, Schlee M, Hartmann G, Pogge von Strandmann E, Coch C.

Oncoimmunology. 2016 Aug 19;5(10):e1219827. eCollection 2016.

14.

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.

Stingl JC, Kaumanns KL, Claus K, Lehmann ML, Kastenmüller K, Bleckwenn M, Hartmann G, Steffens M, Wirtz D, Leuchs AK, Benda N, Meier F, Schöffski O, Holdenrieder S, Coch C, Weckbecker K.

BMC Fam Pract. 2016 Apr 26;17:49. doi: 10.1186/s12875-016-0447-6.

15.

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.

Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21.

PMID:
27100354
16.

Cutting Edge: The RIG-I Ligand 3pRNA Potently Improves CTL Cross-Priming and Facilitates Antiviral Vaccination.

Hochheiser K, Klein M, Gottschalk C, Hoss F, Scheu S, Coch C, Hartmann G, Kurts C.

J Immunol. 2016 Mar 15;196(6):2439-43. doi: 10.4049/jimmunol.1501958. Epub 2016 Jan 27.

17.

Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.

Coenen M, Hinze AV, Mengel M, Fuhrmann C, Lüdenbach B, Zimmermann J, Dykstra V, Fimmers R, Viviani R, Stingl J, Holdenrieder S, Müller M, Hartmann G, Coch C.

BMC Pharmacol Toxicol. 2015 Sep 22;16:25. doi: 10.1186/s40360-015-0025-x.

18.

Sequence-specific activation of the DNA sensor cGAS by Y-form DNA structures as found in primary HIV-1 cDNA.

Herzner AM, Hagmann CA, Goldeck M, Wolter S, Kübler K, Wittmann S, Gramberg T, Andreeva L, Hopfner KP, Mertens C, Zillinger T, Jin T, Xiao TS, Bartok E, Coch C, Ackermann D, Hornung V, Ludwig J, Barchet W, Hartmann G, Schlee M.

Nat Immunol. 2015 Oct;16(10):1025-33. doi: 10.1038/ni.3267. Epub 2015 Sep 7.

19.

A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2'O-Methylated Self RNA.

Schuberth-Wagner C, Ludwig J, Bruder AK, Herzner AM, Zillinger T, Goldeck M, Schmidt T, Schmid-Burgk JL, Kerber R, Wolter S, Stümpel JP, Roth A, Bartok E, Drosten C, Coch C, Hornung V, Barchet W, Kümmerer BM, Hartmann G, Schlee M.

Immunity. 2015 Jul 21;43(1):41-51. doi: 10.1016/j.immuni.2015.06.015. Epub 2015 Jul 14.

20.

Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).

Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG.

J Cancer Res Clin Oncol. 2015 May;141(5):839-49. doi: 10.1007/s00432-014-1864-3. Epub 2014 Nov 8.

PMID:
25381063

Supplemental Content

Loading ...
Support Center